Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyDavid M. Ross, Timothy P. Hughes, Susan Branford et al.|Blood|2013Cited by 705
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor FailureTimothy P. Hughes, Dong‐Wook Kim, Philipp le Coutre et al.|New England Journal of Medicine|2019Cited by 464
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk diseaseSusan Branford, Timothy P. Hughes, Paul Wang et al.|Blood|2018Cited by 208
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineSusan Branford, Timothy P. Hughes, David T Yeung et al.|Blood|2014Cited by 198
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CMLSusan Branford, Timothy P. Hughes, David T Yeung et al.|Blood|2013Cited by 177